| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development | 56,473 | |||
| General and administrative | 27,459 | |||
| Total operating expenses | 83,932 | |||
| Loss from operations | -83,932 | |||
| Interest income | 5,736 | |||
| Interest expense | 1,960 | |||
| Other (expense) income, net | -137 | |||
| Total other income, net | 3,639 | |||
| Net loss | -80,293 | |||
| Change in unrealized gains and losses on marketable securities | 354 | |||
| Comprehensive loss | -79,939 | |||
| Net loss per share attributable to common stockholders, basic | -1.26 | |||
| Net loss per share attributable to common stockholders, diluted | -1.26 | |||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic | 63,847,055 | |||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted | 63,847,055 | |||
Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc. (VERA)